Green Mountain Logic reports that CEDRA Clinical Research, one of the USA's pre-eminent contract research organisations, has selected LabPas CT to automate its phase I clinical trial operations
According to Sherilyn Adcock, chief scientific officer at Cedra, "LabPas CT will comprehensively automate our Phase I processes and systems, from recruiting through export to EDC, significantly enhancing both the quality and speed of our existing systems as well as providing new capabilities.
"Green Mountain Logic truly impressed us with its understanding of Phase I services and processes".
John Rosenblum, president and CEO of Green Mountain Logic, noted, "Cedra is a thought leader in the Phase I clinical trials and bioanalytical services contract research arena, with a reputation for quality that is unsurpassed.
"With LabPas CT, Cedra will set the standard for the future of Phase I research data capture and reporting.
"We are honoured to partner with them".
Cedra is the fourth highly regarded clinical research organisation in the last six months to select LabPas.
Others include Advanced Biomedical Research, Arkansas Clinical Research and a major Midwest health facility.
Cedra Clinical Research has enrolled more than 11,000 volunteers in Phase I clinical trials and has conducted more than 600 Phase I - IV research studies.
The Cedra Clinical Research San Antonio facility includes 200+ Phase I beds and a state-of-the-art clinical reference laboratory.
There are 100+ Phase I beds in the Cedra Clinical Research Austin facility.
Both facilities have planned expansions in space and services in 2007.
Green Mountain Logic's LabPas CT is the leading software solution for Phase I clinical trials, comprehensively integrating data from recruiting through EDC.
LabPas CT deploys PDAs on clinic floors to scan patient and collection vessel barcodes, eliminating the potential for errors.
It provides real-time electronic data entry for collection times, comments, dosing, vital signs and adverse events.
LabPas CT is also unique in its ability to adapt to individual study environments and changing protocols, rather than burdening CROs with the need to adapt to the software.
